Abstract
Objective
To probe doctors’ attitudes and reveal wrong perception in the management of acute gouty attacks.
Design
A descriptive study using a designed questionnaire that was completed through face to face interviews in hospitals, health units and polyclinics in the Makah Region.
Method
This is a qualitative study of treatment by 99 doctors conducted in the second half of 2012. The sample included orthopedists, rheumatologists, general practitioners and family physicians.
Results
72 (72.7%) doctors started treatment of acute attacks with mono-therapy. 58 doctors (58.6%) started with NSAIDs. Indomethacin was the most frequent prescribed NSAIDs. 18 doctors (18.2%) prescribed Allopurinol as the first drug of choice.
42 doctors (43.8%) started Allopurinol “2 weeks after acute attack”. 31 doctors (32.3%) mentioned that they used 100 mg daily dose. 41 doctors (42.7%) mentioned that the starting dose depends on the patient’s condition. Allopurinol was prescribed once daily by 37 doctors (38.9%). 53 doctors (55.8%) used Allopurinol as prophylaxis.
The most frequent test requested was a 24-h urine test for uric acid. In case patients were already on Allopurinol and presented with an acute attack of gout; 33 doctors (34.7%) tended to “increase the dose”.
The most important factor in adjusting the Allopurinol dose is Serum Uric Acid Level. 37 doctors (39.4%) mentioned that they ask for Serum Uric Acid Level every 3–4 weeks.
Conclusion
There were common pitfalls that need a training program to increase awareness of doctors with general guidelines and recommendations. The most critical pitfalls include prescribing Allopurinol in acute gouty attacks and ignoring the Renal Function Test.
1 Introduction
Gout is a pathological and clinical disorder which is mainly characterized by hyperuricemia; which is an increase in serum urate levels of 7.0 mg/dl in men or greater than 6.0 mg/dl in women.Citation1,Citation2 Tophi are a pathognomonic feature of gout detectable by physical examination and/or by imaging approaches and pathology examination.Citation3–Citation4Citation5 Typically, the disease initially presents as acute episodic arthritis then manifests as chronic arthritis of one or more joints.Citation1,Citation2
Gout is one of the most common rheumatic diseases of adulthood, with a self-reported prevalence. In USA it was recently estimated as 3.9% of adults (∼8.3 million people).Citation6 In Saudi Arabia, 8.42% of the study population had hyperuricemia but no case of gout was found.Citation7 Compared with women, men have a four- to nine-folds increased risk of developing gout.Citation8
1.1 Treatment of acute attacks
The choice mainly depends on whether the patient has concomitant health problems or not (e.g.: peptic ulcer or renal insufficiency). There are various treatment options, such as corticosteroids, NSAIDs, ACTH and colchicine. Colchicine is now rarely used. An intra-articular steroid injection is preferred when an easily accessible large joint is involved and when comorbid conditions exist limiting the use of colchicine and NSAIDs. Reasonably septic arthritis must be excluded.Citation9–Citation10Citation11
Patients with no underlying health problems and having an acute gouty attack, are usually prescribed with NSAIDs as drugs of choice. Most NSAIDs can be used, however, indomethacin is the NSAID conventionally chosen for acute gout. An agent with a quick onset of action is selected. Aspirin is not recommended since it can lengthen and strengthen the acute attack, since it can change Uric Acid Levels.
1.2 Colchicine
Is now less commonly used than NSAIDs, due to its narrow therapeutic window and risk of toxicity. Although, it was once the treatment of choice for acute gout.Citation12,Citation13
1.3 Combination therapy
If the patient does not have an adequate response to initial therapy with a single drug, guidelines advice that adding a second appropriate agent is acceptable. Using combination therapy from the start is appropriate for an acute, severe gout attack, particularly if the attack involves multiple large joints or is poly-articular.Citation14
1.4 Treatment of chronic gout
As first line pharmacological approach, guidelines recommend either Allopurinol or febuxostat with xanthine oxidase inhibitor therapy with gout patients who have renal disease.
Guidelines advice, however, state that mono-therapy in patients with creatinine clearance less than 50 mL/min with probenecid is not a first line choice,Citation15 since probenecid may also cause drug interactions.
1.5 Prophylaxis
Some drugs can alter the levels of tissue and serum uric acid, causing acute attacks of gout, such as probenecid, Allopurinol and febuxostat. Accordingly low dose NSAID or colchicine is given for 6 months at least in order to decrease this unfavorable effect. Low doses of prednisone are sometimes given when the patients cannot take either colchicine or NSAIDs.
1.6 Allopurinol
It should be started at a low dose of 100 mg per day, but can be titrated to 800 mg per day as necessary for a patient to achieve the target SUA level of 6.0 mg/dl.Citation16–Citation17Citation18 It has been recommended that patients with renal impairment should receive lower doses. Allopurinol can be used in combination with probenecid. Stopping Allopurinol is not recommended during acute attacks.Citation19
Aim of the study to probe doctors’ attitudes and reveal wrong perception in the management of acute gouty attacks.
2 Methodology
This is a qualitative research in which 99 physicians were face-to-face interviewed through a structured questionnaire. Physicians were from the Makah Region – Saudi Arabia and essentially involved in gout management. Interviews were conducted in the second half of 2012.
The objective of the study is to describe physicians’ prescribing habits in the treatment of gout and whether or not matching the general guidelines and recommendations.
The sample included orthopedists, rheumatologists, general practitioners and family physicians withdrawn from hospitals, health units and polyclinics.
3 Results
99 doctors were asked 17 questions about their experience with acute gout attack.
shows treatment of choice; mono vs. combined therapy, first line of choice and first NSAID of choice.
The most common indication of initiating urate lowering agents in patients with acute gouty attack is Serum Uric Acid Level, mentioned by 67 doctors (68.4%) followed by the presence of Tophi (44–44.9%), history of Renal Stones (41–41.8%) and history of 2 or more severe attacks (36–36.7%). Less frequent indications are history of renal failure (28–28.6%), 24 h urine uric acid level (20–20.4%), Joint X-ray changes (19–19.4%), age (15–15.3%), history of co-morbid diseases (14–14.3%) and history of severe single attack (13–13.3%). The least frequent indications were sex, thyroid disease, specific indication and race. Each doctor mentioned an average of 3.2 indications.
shows the use of ULT; Treatments used as a prophylaxis to prevent recurrent attacks, when doctors start ULT, Starting Dose of ULT (Allopurinol) and Frequency of using ULT per day.
shows tests that doctors like to order in following up patients.
In case the patient was already on Allopurinol and presented with an acute attack of gout, 33 doctors (34.7%) tend to “increase the dose”, 30 doctors (31.6%) tend to “stop it and continue after the attack”, 23.2% tend to “continue on the same dose”, 5.3% “decrease the dose” and 5.3% will stop it completely.
The most important factor in adjusting Allopurinol dose is the Serum Uric Acid Level, mentioned by 76 doctors (79.2%), Renal Function (serum creatinine) mentioned by 56 doctors (58.3%), “number of attacks” mentioned by 27 doctors (28.1%) and “24-h Urine Uric Acid Level” mentioned by 25 doctors (26%). Each doctor mentioned an average of 1.91 answers.
Frequency of serum uric acid test; 1 doctor (1.1%) “every 1–2 weeks”, 37 doctors (39.4%) mentioned “every 3–4 weeks”, 19 doctors (20.2%) “every 5–6 weeks”, 29 doctors (30.9%) “every 7–8 weeks” and 8 doctors (8.5%) mentioned that they do not use it for follow up.
The most important precipitating factors that doctors consider are Alcohol (mentioned by 60 doctors 62.5%), obesity (53–55.2%), thiazide or lasix (48–50%) and low dose of aspirin (18–18.8%).
Factors which are considered when prescribing uricosuric agents are; Renal Function Tests (mentioned by 73 doctors – 76%), History of Renal Stones (57–59.4%), Measuring 24-h Urine Uric Acid (39–40.6%) and age (31–32.3%). Each doctor mentioned an average of 2.15 answers.
4 Discussion
A sample of 99 doctors from the Makah Region were face-to-face interviewed to describe their attitudes in the management of acute gouty attacks and to find out whether doctors follow general guidelines and recommendations or not.
72 doctors (72.7%) started the treatment of acute gouty attacks with mono-therapy which matches to general guidelines and recommendations.Citation15
58 doctors (58.6%) started treatment with NSAIDs which matches the guidelines. 34 doctors (34.3%) use Oral Colchicine which is the second choice of general guidelines and recommendations. 18 doctors (18.2) use Allopurinol which is not recommended by the guidelines in acute attacks and is considered a big mistake in the management of acute attacks and 14 doctors (14.1%) use steroids which is the third choice of the guidelines.Citation15
Indomethacin is the most frequent prescribed NSAID, mentioned by 41 doctors (41.8%) followed by Profen and Diclofenac by 21 doctors (21.4%) for each of them followed by Meloxicam by 10 doctors (10.1%) and Celecoxib & Naproxen by 6 doctors (6.1%) for each of them ().
Only 53 doctors (55.8%) used Allopurinol as prophylaxis to prevent recurrent attacks which matches with guidelines. 22 doctors (23.2%) use uricosuric agents, 16 doctors (16.8%) Colchicine and 12 doctors (12.6%) use NSAIDs.Citation16–Citation17Citation18
42 doctors (43.8%) started Allopurinol 2 weeks after acute attack which matches with guidelines. On the other hand, 12 doctors (12.5%) started Allopurinol 4-weeks later, 29 doctors (30.2%) started Allopurinol “Immediately” which is also a common mistake and does not match the guidelines.Citation16–Citation17Citation18
General guidelines and recommendations advise that the dosage of Allopurinol should be started at a low dose of 100 mg per day.Citation16–Citation17Citation18 Only 31 doctors (32.3%) mentioned that they started with a 100 mg dose while 9 doctors (9.4%) started with 200 mg and 18 doctors (18.8%) started with 300 mg/day. 41 doctors (42.7%) refused to recommend a certain dosage as a starting dose as it depends on the patient’s condition.
Allopurinol is prescribed once daily by 37 doctors (38.9%), which matches with guidelines. BID is reported by 16 doctors (16.8%) and TID by 6 doctors (6.3%). 33 doctors (34.7%) mentioned that it depends on the case while 3 doctors (3.2%) do not use Allopurinol.
Only 44 doctors (45%) consider the Serum Creatinine (Renal Functions) test as a very important test in Allopurinol dose adjustment ().
Guidelines advise not to stop Allopurinol in case the patient is presented by an acute attack of gout and is already on Allopurinol.Citation19 However, in our study the results have shown that 23.2% of the doctors “continue on the same dose”, 34.7% tend to “increase the dose”, 31.6% tend to “stop it and continue after the attack”, 5.3% “decrease the dose” and 5.3% will “stop it completely”. Renal Function Tests and serum uric acid are important factors in adjusting the Allopurinol dose. Only 79.2% of the doctors reported the Serum Uric Acid Level, 58.3% mentioned Renal Function (creatinine), 28.1% mentioned “number of attacks” and 26% mentioned “24-h urine Uric Acid Level”.Citation15
Guidelines recommend testing the Uric Acid Level every 3–4 weeks to adjust the Allopurinol dose. Only 37 doctors (39.4%) mentioned “every 3–4 weeks”, 19 doctors (20.2%) “every 5–6 weeks”, 29 doctors (30.9%) “every 7–8 weeks” and 1 doctor (1.1%) “every 1–2 weeks”. 8 doctors (8.5%) mentioned that they do not use it for follow up.Citation19
Factors which are considered when prescribing uricosuric agents are; Renal Function Tests (mentioned by 73 doctors – 76%), History of Renal Stones (57–59.4%), measuring 24-h urine uric acid (39–40.6%) and Age (31–32.3%), which does not match with general guidelines and recommendations.Citation16–Citation17Citation18
5 Conclusion
A considerable number of doctors do not follow general guidelines and recommendations in managing acute gouty attacks. There were common pitfalls that need a training program to increase the awareness of doctors with the general guidelines and recommendations.
Common pitfalls were
• | Management of acute attacks:
| ||||||||||||||||||||||||||||
• | Prophylaxis therapy:
| ||||||||||||||||||||||||||||
• | Allopurinol and recurrent attacks:
| ||||||||||||||||||||||||||||
• | Follow up and Allopurinol dose adjustment:
|
Recommendations
Increase the level of awareness, by doing seminars and printing brochures to correct these misconceptions and pitfalls. Further studies are recommended.
Disclosure
(1) | Authorship contribution: Not Applicable. | ||||
(2) | Disclosure of competing interest: Not Applicable. | ||||
(3) | Disclosure of sponsorship: Not Applicable. |
Notes
Peer review under responsibility of Alexandria University Faculty of Medicine.
Available online 17 May 2014
References
- T.NeogiClinical practice: goutN Engl J Med3642011443 52
- R.TerkeltaubUpdate on gout: new therapeutic strategies and optionsNat Rev Rheumatol6201030 8
- N.DalbethO.AatiA.GaoAssessment of tophus size: a comparison between physical measurement methods and dual-energy computed tomography scanningJ Clin Rheumatol18201223 7
- N.DalbethB.ClarkK.GregoryMechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomographyAnn Rheum Dis6820091290 5
- M.A.DesaiJ.J.PetersonH.W.GarnerClinical utility of dual-energy CT for evaluation of tophaceous goutRadiographics3120111365 75
- Y.ZhuB.J.PandyaH.K.ChoiPrevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008Arthritis Rheum6320113136 41
- A.S.Al-ArfajHyperuricemia in Saudi ArabiaRheumatol Int202200061 4
- L.AnnemansE.SpaepenM.GaskinGout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005Ann Rheum Dis672008960966
- P.ReberX.CrevoisierB.NoesbergerUnusual localisation of tophaceous gout. A report of four cases and review of the literatureArch Orthop Trauma Surg11551996297299
- D.SchapiraS.StahlO.B.IzhakChronic tophaceous gouty arthritis mimicking rheumatoid arthritisSemin Arthritis Rheum29119995663
- C.P.ShoganC.L.FolioTophaceous gout and rheumatoid arthritis awarenessJ Am Osteopath Assoc10872008352 3
- Medsafe Pharmacovigilance Team. Colchicine: lower doses for greater safety Publishing; 2005. http://www.medsafe.govt.nz/profs/puarticles/colchdose.htm (Accessed November 2005).
- G.NukiColchicine: its mechanism of action and efficacy in crystal-induced inflammationCurr Rheumatol Rep102008218227
- D.KhannaP.P.KhannaJ.D.Fitzgerald2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and anti-inflammatory prophylaxis of acute gouty arthritisArthritis Care Res641020121447 61
- D.KhannaJ.D.FitzgeraldP.P.Khanna2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic non pharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care Res641020121431 46
- J.ChaoR.TerkelatubA critical reappraisal of Allopurinol dosing, safety and efficacy for hyperuricemia in goutCurr Rheumatol Rep112009135140
- M.K.ReindersC.HaagsmaT.L.JansenArandomised controlled trial on the efficacy and tolerability with dose escalation of Allopurinol 300–600 mg/day versus benzobromaron 100–200 mg/day in patients with goutAnn Rheum Dis6862009892897
- B.ArrolM.BennettN.DalbethMore Allopurinol is needed to get gout patients<0.36 mmol/l: a gout audit in the form of a before-after trial.J prim Health Care.142009315318
- H.HarrisConsultant Rheumatologist Review approved on behalf of NHS Fife by the Fife Area Drugs & Therapeutics CommitteeBPJ3720113440